Pharma is built to overcome, but focus on fundamentals remains key.
Arda Ural, PhD
Advertisement
Arda Ural, Ph.D., is the Americas Industry Markets Leader for Health Sciences and Wellness at Ernst & Young LLP (EY). Arda oversees the life sciences team that covers industry mergers and acquisitions.
Articles by Arda Ural, PhD
A recent analysis of the biotech market shows promising signs.
The recent flurry of Q1 earnings reports offer a unique opportunity to assess the real-time impacts of COVID-19 on the sector.
Considerations for biopharma to transform itself beyond the COVID-19 crisis, by Arda Ural.
Advertisement
Latest Updated Articles
Biopharma Q1 Earnings: The Impact of COVID-19May 21st 2021
- Navigating the Recession and Patent Expirations
July 6th 2023
Leading Through a Historical SingularityMay 28th 2020
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Wegovy HD Injectable Under Accelerated Approval
2
Pharma M&A Roundup: Novartis to Acquire Pan-Mutant-Selective PI3Kα Inhibitor from Synnovation Therapeutics, Collegium to Acquire Azstarys from Corium Therapeutics
3
What Are the ‘Last Mile Issues’ Impacting Pharma?
4
Surfacing Themes at Access USA 2026
5